Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 16/20 | 0.60 |
| ▸ | ESR1 | P03372 | 15/20 | 0.60 |
| ▸ | UTRN | P46939 | 1/20 | 0.56 |
| ▸ | KDM6B | O15054 | 1/20 | 0.52 |
| ▸ | KDM6A | O15550 | 1/20 | 0.52 |
| ▸ | C1R | P00736 | 1/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12704756 | 0.89 | ESR2 (0.63) | ESR2ESR1UTRNKDM6BKDM6A | |
| SCHEMBL27621439 | 0.84 | UTRN (0.52) | ESR2ESR1UTRNKDM6BKDM6A | |
| SCHEMBL24292359 | 0.82 | C1R (0.64) | UTRNKDM6BKDM6AC1R | |
| SCHEMBL439113 | 0.82 | UTRN (0.54) | UTRNC1R | |
| SCHEMBL9115528 | 0.81 | ESR1 (0.65) | ESR2ESR1KDM6BKDM6APIK3CA | |
| SCHEMBL12707323 | 0.80 | UTRN (0.53) | UTRNC1R | |
| SCHEMBL12909701 | 0.80 | UTRN (0.53) | ESR2ESR1UTRNC1R | |
| SCHEMBL1378665 | 0.76 | ESR1 (1.00) | ESR2ESR1KDM6BKDM6APIK3CA | |
| SCHEMBL1375754 | 0.75 | ESR1 (1.00) | ESR2ESR1KDM6BKDM6APIK3CA | |
| SCHEMBL6448557 | 0.75 | ESR2 (0.60) | ESR2ESR1KDM6BKDM6APIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338459-B2 | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | FOLDRX PHARMACEUTICALS, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338459-B2 | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | FOLDRX PHARMACEUTICALS, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2314584-A1 | 2-(heteroaryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | Foldrx Pharmaceuticals, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20110092545-A1 | Compounds, Compositions and Methods for Stabilizing Transthyretin and Inhibiting Transthyretin Misfolding | FoldRx Pharmaceuticals, Inc., a Massachusetts corporation | 2011-04-21 | — | — | US | disclosed |
| US-20110092545-A1 | Compounds, Compositions and Methods for Stabilizing Transthyretin and Inhibiting Transthyretin Misfolding | FoldRx Pharmaceuticals, Inc., a Massachusetts corporation | 2011-04-21 | — | — | US | disclosed |
| US-7868033-B2 | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | FOLDRX PHARMACEUTICALS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868033-B2 | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | FOLDRX PHARMACEUTICALS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| EP-1339701-B1 | HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-6849632-B2 | Heteroaryl alkyl piperazine derivatives | CV THERAPEUTICS, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040192702-A1 | Heteroaryl alkyl piperazine derivatives | ZABLOCKI JEFF (US) | 2004-09-30 | — | — | US | disclosed |
| US-20040029889-A1 | Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. | 2004-02-12 | — | — | US | disclosed |
| US-20030216409-A1 | Heteroaryl alkyl piperazine derivatives | CV THERAPEUTICS, INC. | 2003-11-20 | — | — | US | disclosed |
| EP-1339701-A1 | HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6573264-B1 | Protecting skeletal muscles against damage, treating shock conditions, preserving donor tissue and organs used in transplants, treating cardiovascular diseases | CV THERAPEUTICS, INC. | 2003-06-03 | — | — | US | disclosed |
| WO-2002064576-A1 | HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029889-A1 | Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors | CPT1B, CPT1A, ALOX15 | ESR2 3010/4885ESR1 4756/4885UTRN 3383/4885 |
| US-20040192702-A1 | Heteroaryl alkyl piperazine derivatives | ATP2A1, CPT1B, ATP2A3 | ESR2 3636/4885ESR1 4830/4885UTRN 1904/4885 |
| US-20110092545-A1 | Compounds, Compositions and Methods for Stabilizing Transthyretin and Inhibiting Transthyretin Misfolding | TTR, ALB, TTPA | ESR2 3910/4885ESR1 2658/4885UTRN 266/4885 |
| US-20030216409-A1 | Heteroaryl alkyl piperazine derivatives | ATP2A1, CPT1B, ATP2A3 | ESR2 3636/4885ESR1 4830/4885UTRN 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.